218 related articles for article (PubMed ID: 18252268)
1. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
Bartha R; Smith M; Rupsingh R; Rylett J; Wells JL; Borrie MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):786-93. PubMed ID: 18252268
[TBL] [Abstract][Full Text] [Related]
2. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Penner J; Rupsingh R; Smith M; Wells JL; Borrie MJ; Bartha R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):104-10. PubMed ID: 19833161
[TBL] [Abstract][Full Text] [Related]
3. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Wang Z; Zhao C; Yu L; Zhou W; Li K
Acta Radiol; 2009 Apr; 50(3):312-9. PubMed ID: 19235582
[TBL] [Abstract][Full Text] [Related]
4. Reduced hippocampal glutamate in Alzheimer disease.
Rupsingh R; Borrie M; Smith M; Wells JL; Bartha R
Neurobiol Aging; 2011 May; 32(5):802-10. PubMed ID: 19501936
[TBL] [Abstract][Full Text] [Related]
5. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
6. 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease.
Henigsberg N; Kalember P; Hrabać P; Rados M; Bajs M; Rados M; Kovavić Z; Loncar M; Madzar T
Coll Antropol; 2011 Jan; 35 Suppl 1():159-62. PubMed ID: 21648328
[TBL] [Abstract][Full Text] [Related]
7. Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Watanabe T; Shiino A; Akiguchi I
Dement Geriatr Cogn Disord; 2008; 26(1):89-100. PubMed ID: 18617735
[TBL] [Abstract][Full Text] [Related]
8. Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Pilatus U; Lais C; Rochmont Adu M; Kratzsch T; Frölich L; Maurer K; Zanella FE; Lanfermann H; Pantel J
Psychiatry Res; 2009 Jul; 173(1):1-7. PubMed ID: 19427767
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
10. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Meyerhoff DJ; MacKay S; Constans JM; Norman D; Van Dyke C; Fein G; Weiner MW
Ann Neurol; 1994 Jul; 36(1):40-7. PubMed ID: 8024260
[TBL] [Abstract][Full Text] [Related]
11. Treatment monitoring and response prediction with proton MR spectroscopy in AD.
Jessen F; Traeber F; Freymann K; Maier W; Schild HH; Block W
Neurology; 2006 Aug; 67(3):528-30. PubMed ID: 16894124
[TBL] [Abstract][Full Text] [Related]
12. Effects of donepezil on brain morphometric and metabolic changes in patients with Alzheimer's disease: A DARTEL-based VBM and (1)H-MRS.
Moon CM; Kim BC; Jeong GW
Magn Reson Imaging; 2016 Sep; 34(7):1008-16. PubMed ID: 27131829
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
14. Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
Nilsen LH; Melø TM; Saether O; Witter MP; Sonnewald U
J Neurochem; 2012 Nov; 123(4):532-41. PubMed ID: 22943908
[TBL] [Abstract][Full Text] [Related]
15. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.
Griffith HR; den Hollander JA; Stewart CC; Evanochko WT; Buchthal SD; Harrell LE; Zamrini EY; Brockington JC; Marson DC
NMR Biomed; 2007 Dec; 20(8):709-16. PubMed ID: 17295394
[TBL] [Abstract][Full Text] [Related]
16. Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Azevedo D; Tatsch M; Hototian SR; Bazzarella MC; Castro CC; Bottino CM
Dement Geriatr Cogn Disord; 2008; 25(6):491-500. PubMed ID: 18441524
[TBL] [Abstract][Full Text] [Related]
17. Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.
Chen SQ; Cai Q; Shen YY; Wang PJ; Teng GJ; Zhang W; Zang FC
Behav Brain Res; 2012 Nov; 235(1):1-6. PubMed ID: 22828014
[TBL] [Abstract][Full Text] [Related]
18. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
19. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
[TBL] [Abstract][Full Text] [Related]
20. Proton magnetic resonance spectroscopy of late-life major depressive disorder.
Chen CS; Chiang IC; Li CW; Lin WC; Lu CY; Hsieh TJ; Liu GC; Lin HF; Kuo YT
Psychiatry Res; 2009 Jun; 172(3):210-4. PubMed ID: 19303260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
